Stock Events

Histogen 

$0.21
28
+$0.01+4.48% Friday 18:17

Statistik

Harga Tertinggi Hari
0.21
Harga Terendah Hari
0.21
52M Tertinggi
1.05
52M Terendah
0.05
Volum
287
Volum Purata
16,688
Kapasiti Pasaran
897,069
Nisbah P/E
-0.07
Pendapatan Dividen
-
Dividen
-

Pendapatan

9NovDisahkan
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
-1.7
-1.2
-0.7
-0.2
EPS yang dijangka
-0.54
EPS sebenar
-0.9

Orang Lain Juga Mengikuti

Senarai ini berdasarkan senarai pantau orang di Stock Events yang mengikuti HSTO. Ini bukan cadangan pelaburan.

Peserta

Senarai ini adalah analisis berdasarkan peristiwa pasaran terkini. Ini bukan cadangan pelaburan.

Mengenai

Health Technology
Biotechnology
Pharmaceuticals: Major
Manufacturing
Pharmaceutical Preparation Manufacturing
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
Show more...
CEO
Steven Mento
Pekerja
7
Negara
US
ISIN
US43358Y2028
WKN
000A3DMJS

Penyenaraian